Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development

Monoclonal antibody (mAb)-based therapeutics are the fastest growing class of human pharmaceuticals. They are typically IgG1 molecules with N-glycans attached to the N297 residue on crystallizable fragment (Fc). Different Fc glycoforms impact their effector function, pharmacokinetics, stability, agg...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Li, Wei, Zhu, Zhongyu, Chen, Weizao, Feng, Yang, Dimitrov, Dimiter S.
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2017
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693878/
https://ncbi.nlm.nih.gov/pubmed/29181010
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.01554
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars